Alcon AG vs Avantis International Small Cap Value ETF — how do they compare? Alcon AG trades at $73.99 (market cap $36.44B), while Avantis International Small Cap Value ETF trades at $110.2. The key difference: Alcon AG pays a 0.48% dividend while Avantis International Small Cap Value ETF pays none, and Avantis International Small Cap Value ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | AVDV | |
|---|---|---|
Market Cap | $36.44B | — |
Sector | Health | Sector/Thematic |
52-Week High | $90.12 | $110.40 |
52-Week Low | $62.02 | $83.89 |
Enterprise Value | $40.28B | — |
Dividend Yield | 0.48% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.59, down slightly by 0.05% today, with a bullish technical signal from moving averages and a consensus analyst price target of $86.67 implying 17.8% upside. Recent Q2 2026 earnings beat estimates with EPS of $0.84 versus $0.77 expected, and the company raised its 2026 profitability outlook, driving positive investor sentiment. Revenue growth has been steady, reaching $10.40 billion in 2025, though net income margin dipped to 5.92%.
The outlook is positive given strong earnings beats, raised guidance, and bullish analyst ratings, but risks include elevated P/E of 57.52, high RSI levels suggesting overbought conditions, and margin pressures from rising costs. Institutional ownership trends and recent collaborations, like with RxSight, support growth, yet macroeconomic and competitive factors warrant caution.
AVDV trades at $110.28, up 0.75% today, with a bullish technical signal from moving averages but caution from overbought oscillators. The stock shows strength near resistance at $110, supported by positive media coverage highlighting international small-cap value performance and a forthcoming dividend. Recent news notes a 21% return since November 2025, driven by commodity exposure that has since cooled.
Outlook remains positive due to strong momentum and dividend yield, but risks include overbought conditions and reliance on international markets. Investors should weigh technical indicators against fundamental growth prospects in developed ex-US small caps.
Trailing returns across standard periods
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →